IL13

Chr 5AD

interleukin 13

Also known as: IL-13, P600

This gene encodes an immunoregulatory cytokine produced primarily by activated Th2 cells. This cytokine is involved in several stages of B-cell maturation and differentiation. It up-regulates CD23 and MHC class II expression, and promotes IgE isotype switching of B cells. This cytokine down-regulates macrophage activity, thereby inhibits the production of pro-inflammatory cytokines and chemokines. This cytokine is found to be critical to the pathogenesis of allergen-induced asthma but operates through mechanisms independent of IgE and eosinophils. This gene, IL3, IL5, IL4, and CSF2 form a cytokine gene cluster on chromosome 5q, with this gene particularly close to IL4. [provided by RefSeq, Jul 2008]

Primary Disease Associations & Inheritance

{Allergic rhinitis, susceptibility to}MIM #607154
{Asthma, susceptibility to}MIM #600807
AD
30
ClinVar variants
14
Pathogenic / LP
0.01
pLI score
12
Active trials
Clinical SummaryIL13
Population Constraint (gnomAD)
Low constraint (pLI 0.01) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
14 Pathogenic / Likely Pathogenic· 10 VUS of 30 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.63LOEUF
pLI 0.014
Z-score 0.62
OE 0.68 (0.311.63)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.37Z-score
OE missense 0.89 (0.731.07)
75 obs / 84.7 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.68 (0.311.63)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.89 (0.731.07)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.81
01.21.6
LoF obs/exp: 3 / 4.4Missense obs/exp: 75 / 84.7Syn Z: 0.91

ClinVar Variant Classifications

30 submitted variants in ClinVar

Classification Summary

Pathogenic13
Likely Pathogenic1
VUS10
Likely Benign4
Benign2
13
Pathogenic
1
Likely Pathogenic
10
VUS
4
Likely Benign
2
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
13
0
13
Likely Pathogenic
0
0
1
0
1
VUS
0
8
2
0
10
Likely Benign
0
2
2
0
4
Benign
0
1
0
1
2
Total01118130

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

IL13 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

INTERLEUKIN 13; IL13
MIM #147683 · *

{Allergic rhinitis, susceptibility to}

MIM #607154

Molecular basis of disorder known

{Asthma, susceptibility to}

MIM #600807

Molecular basis of disorder known

Autosomal dominant
📖
GeneReview available — IL13
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Macrophage plasticity, polarization, and function in health and disease.
Shapouri-Moghaddam A et al.·J Cell Physiol
2018Review
Asthma Phenotypes and Biomarkers.
Grunwell JR et al.·Respir Care
2025Review
Targeting key proximal drivers of type 2 inflammation in disease.
Gandhi NA et al.·Nat Rev Drug Discov
2016Review
Alternative activation of macrophages.
Gordon S·Nat Rev Immunol
2003Review
Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C et al.·Front Immunol
2020Review
Top 10 resultsSearch PubMed ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Multiple SclerosisSpasticity

miR-142-3p as Potential Biomarker of Synaptopathy in MS

RECRUITING
NCT03999788Phase NANeuromed IRCCSStarted 2019-12-10
lumbar puncture and blood withdrawalIntermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity
Non-Alcoholic Fatty Liver Disease

Aronia and Non-alcoholic Fatty Liver Disease

NOT YET RECRUITING
NCT06450769Phase NAIstanbul Kent UniversityStarted 2024-06-15
Aronia juiceMediterranean dietLow-fat diet
DysferlinopathyMiyoshi MyopathyLGMDR2

Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy (LGMD R2) in the RF

ENROLLING BY INVITATION
NCT04824040Artgen BiotechStarted 2020-01-15
HIV

Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1

ACTIVE NOT RECRUITING
NCT07028385Phase PHASE2Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaStarted 2025-09-22
Bariticinib 2 mgPlacebo
Atopic DermatitisEczema

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

ACTIVE NOT RECRUITING
NCT01782703Northwestern UniversityStarted 2013-01
Idiopathic Intracranial Hypertension

Biomarkers in the Etiology of Idiopathic Intracranial Hypertension

RECRUITING
NCT06059703Phase NAUniversity Hospital, MontpellierStarted 2023-11-27
Blood punctionCentral blood samplingIntracranial pressure measurement
Hereditary TransmissionImmune DevelopmentChildhood Obesity

Maternal Grandmothers in the Born in Guangzhou Cohort Study

RECRUITING
NCT03633162Guangzhou Women and Children's Medical CenterStarted 2018-05-21
Non-Allergic Rhinitis With Eosinophilia Syndrome

Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome

NOT YET RECRUITING
NCT07240376Phase NAHuazhong University of Science and TechnologyStarted 2025-11-25
Stapokibart (CM310)Placebo
Epigenetic Effects of Intranasal SteroidsEnvironmental Exposure

Epigenetic Health Benefits of Budesonide

ACTIVE NOT RECRUITING
NCT04342039Phase PHASE4University of British ColumbiaStarted 2021-01-07
Budesonide NasalPlacebo
Endometriosis

Developing a Complex ex Vivo Endometrial Tissue Model to Improve Endometriosis Care

RECRUITING
NCT06331676Phase NAHospices Civils de LyonStarted 2024-06-21
Tissue collectionData collection
Ulcerative Colitis

Multi-Strain Probiotics Supplementation With Standard Care in Mild to Moderate Ulcerative Colitis

RECRUITING
NCT06595719Phase NANational University of MalaysiaStarted 2024-02-23
Multi-Strain ProbioticsPlacebo
Gut MicrobiotaGastrointestinal SymptomsTemperament

Mother-Infant Cohort Study in Malaysia and China

RECRUITING
NCT04919265Universiti Putra MalaysiaStarted 2022-06-03
No intervention - mother-infant cohort study